Pinealon peptide: what the research shows, what it does not, and how it is sold

Pinealon is one of the short synthetic peptides that Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology call peptide bioregulators. It is a tripeptide made of three amino acids, glutamic acid, aspartic acid and arginine, written Glu-Asp-Arg or EDR. The group’s papers describe it as a peptide with neuroprotective properties, meaning it is studied for effects on nerve cells rather than on the pineal gland that its name suggests ^{[1] [2]}. In some of the group’s cell-culture papers it appears under the laboratory code T-33 ^[13].

The Khavinson bioregulator series began in the 1970s with extracts of animal organs, such as the thymus extract thymalin and the pineal extract epithalamin. The group later designed very short peptides based on the amino-acid composition of those extracts, of which epitalon (Ala-Glu-Asp-Gly) is the best known. Pinealon belongs to the same family as cortagen, cardiogen, bronchogen, cartalax and vilon. Each is claimed to act on a particular tissue, and the pinealon bioregulator is the one claimed to act on the brain.

Two points should be made plainly before looking at the research. First, almost everything published about pinealon comes from one group of authors in St Petersburg and their collaborators, much of it in Russian-language journals such as Advances in Gerontology, with the English-language papers mostly appearing in the Bulletin of Experimental Biology and Medicine and in open-access journals. Independent replication by unconnected laboratories is scarce. Second, the human evidence consists of small, uncontrolled reports; there is no randomised trial of pinealon for any condition.

The Khavinson group’s central hypothesis is that very short peptides pass into cells and the cell nucleus and bind DNA or histone proteins, changing which genes are switched on. In a 2011 study, fluorescently labelled pinealon, epitalon and testagen were seen in the cytoplasm, nucleus and nucleolus of HeLa cells, and the peptides quenched the fluorescence of labelled DNA fragments in a sequence-dependent way, which the authors took as evidence of specific peptide-DNA binding ^[7]. A 2019 physical chemistry study by a different St Petersburg group used NMR, viscosity and molecular dynamics to show that EDR can partly enter the major groove of DNA and interact with guanine bases, an interaction promoted by magnesium ions ^[8].

In the 2020 review that summarises the group’s work on the EDR peptide, the authors propose that pinealon enters cells, binds histones or nucleic acids, and changes the activity of the MAPK/ERK signalling pathway and the synthesis of proteins including caspase-3, p53, the antioxidant enzymes SOD2 and GPX1, the transcription factors PPARA and PPARG, serotonin and calmodulin ^[2]. A 2021 modelling study found possible EDR binding sites in the promoter regions of the CASP3, NES, GAP43, APOE, SOD2, PPARA and PPARG genes, all involved in Alzheimer’s disease ^[5]. A 2023 docking study argued that EDR and 25 other short peptides could enter cells through the LAT1, LAT2 and PEPT1 amino-acid and peptide transporters ^[12].

This is a plausible mechanism and there is laboratory evidence for peptide-DNA contact. What has not been shown is that a dose of pinealon taken by mouth or injection reaches the human brain in a concentration that produces these effects, or that the gene changes seen in cultured cells translate into a clinical benefit.

Searches for pinealon benefits usually turn up claims about memory, brain ageing and protection of nerve cells. The underlying studies are almost all in cells or rodents.

Oxidative stress: the first English-language pinealon paper, published in 2011, reported that the tripeptide limited the build-up of reactive oxygen species in rat cerebellar granule cells, neutrophils and PC12 cells exposed to oxidative stress, and reduced necrotic cell death. The protective effect saturated at low concentrations while effects on the cell cycle continued at higher ones, which the authors read as evidence that pinealon does more than act as an antioxidant ^[1].

Alzheimer’s disease models: in a 2017 study, EDR at 200 ng/mL restored the number of mature (mushroom) dendritic spines in cultured mouse hippocampal neurons exposed to amyloid toxicity, increasing them by 71% and returning them to normal, compared with a 20% increase for the related tripeptide KED ^[6]. A 2021 follow-up in 5xFAD transgenic mice, a model of Alzheimer’s disease, reported that EDR and KED prevented dendritic spine loss; daily intraperitoneal injection of KED at 400 µg/kg from two to four months of age tended to increase neuroplasticity ^[5]. Dendritic spines are one marker of synaptic health, and preserving them in a mouse model is a long way from slowing dementia in people.

Serotonin: a 2014 study reported that EDR and KED stimulated serotonin expression in ageing cultures of rat brain cortex cells and, by molecular docking, found a sequence in the tryptophan hydroxylase gene that the authors proposed the peptides bind ^[4]. In 2015, a group in Rostov-on-Don reported that pinealon and cortexin both raised serotonin in the cortex of 18-month-old rats under mild hypothermia and adrenergic transmitters under acute hypoxia, with cortexin having the stronger effect on free-radical processes and caspase-3 ^[11].

Prenatal protection: a 2012 study gave pinealon to pregnant rats fed excess methionine to induce high homocysteine levels. The offspring showed better spatial orientation and learning, less reactive oxygen species accumulation and fewer necrotic cerebellar neurons than untreated controls ^[3].

Skin cells: in organotypic skin cultures from young rats, EDR (as T-33) stimulated cell proliferation along with three other tripeptides; in cultures from old rats only KED (T-38) had a marked effect. The authors linked the extra proliferation to lower p53 expression and less apoptosis ^[13]. In organotypic pineal gland cultures, by contrast, EDR did not affect the proliferation marker Ki-67 or the apoptosis marker AIF, whereas epitalon and KED did ^[15], which is worth knowing given the name pinealon.

We found no randomised controlled trial of pinealon in PubMed. The 2020 review states that the EDR peptide improves memory issues in elderly patients ^[2], but the primary reports it draws on are in Russian and are small.

The most detailed abstract available in English is a 2015 Russian-language study from Yekaterinburg in which 32 people aged 41 to 83 with multiple chronic conditions and organic brain syndrome in remission received the preparations Pinealon and Vesugen. The authors reported an anabolic effect and improvements in biological-age indicators, and judged vesugen the more effective of the two. They also reported pro-oxidant activity on chemiluminescence and a fall in circulating CD34+ haematopoietic stem-cell markers that they interpreted as inhibition of haematopoiesis. There was no placebo group described in the abstract ^[9].

A 2013 review in the same journal compared the clinical use of polypeptide complexes (cortexin, cerebrolysin) with short peptides (semax, cortagen, pinealon) in elderly people, describing the data as supporting neuroprotective activity, but it is a narrative review from the developing group rather than a trial ^[10]. As of September 2026 there are no pinealon entries on ClinicalTrials.gov that we could find, and no regulator outside Russia has assessed it.

There is no reliable answer, because there is no controlled human trial measuring an outcome over time. In the cell studies, effects on dendritic spines were measured after days in culture ^[6], and in the mouse study the peptide was given daily for two months ^[5]. Khavinson-series peptides are typically sold in Russia as courses of 10 to 30 days, but that schedule comes from the marketing of the products, not from dose-ranging trials.

Published doses are laboratory doses, and none of them is a recommendation. In cultured hippocampal neurons, EDR was used at 200 ng/mL ^[6]. In the 2011 cell study, protective effects on reactive oxygen species saturated at low concentrations ^[1]. In the 5xFAD mouse study the stated dose was for the related peptide KED, 400 µg/kg by intraperitoneal injection daily for two months; the abstract does not give a separate dose for EDR ^[5]. The human report in 32 patients does not give a dose in its English abstract ^[9].

Research peptide suppliers sell pinealon as freeze-dried powder in vials, typically 10 mg or 20 mg, for reconstitution, and some sell it as capsules. No human study has established what dose, if any, is effective by either route, and there is no published pharmacokinetic study showing how much of an oral or injected dose reaches the brain. If you are working with the powder, the peptide calculator and its pinealon page convert vial contents to a concentration.

In the animal studies, pinealon was given by injection (intraperitoneal in mice) ^[5], and in the rat hypoxia work by injection as well ^[11]. In Russia, Khavinson-series short peptides are sold mainly as oral capsules marketed as food supplements rather than as medicines. Research suppliers in the UK, US and Europe sell the peptide as a lyophilised powder for reconstitution, and a smaller number sell capsules. Whether a tripeptide survives digestion and absorption intact is an open question; the 2023 transporter modelling paper argues that EDR could be carried by intestinal peptide transporters, but that is a computer model, not a measurement in people ^[12].

Because there are no controlled human trials, there is no systematic record of pinealon side effects. The Khavinson group’s reviews describe short peptides as having no reported side effects ^[14], but absence of reporting in small uncontrolled studies is not evidence of safety. The one human report with a detailed abstract noted pro-oxidant activity and a fall in circulating CD34+ stem-cell markers during treatment, which the authors themselves flagged for further study ^[9].

A general concern with any peptide that is claimed to change gene expression and to stimulate cell proliferation is its effect on cancer risk. Pinealon reduced p53 expression in rat skin cultures ^[13] and is proposed to bind gene promoters including CASP3 ^[5], both involved in apoptosis. No long-term animal study of pinealon and tumour incidence has been published, unlike for epitalon and the thymalin-derived dipeptide thymogen. We found no data on pinealon in pregnancy beyond the rat study, in which it was given to pregnant animals ^[3], and no data on interactions with medicines.

The practical risks for anyone buying pinealon online are those of any unregulated peptide product: uncertain identity, purity and sterility. Our guides to third-party testing and how to read a certificate of analysis cover what a test report should show.

Pinealon is not an approved medicine in the UK, US, EU, Canada or Australia, and unlike thymalin, it is not a registered medicine in Russia either; there it is sold as a supplement. It is not on the WADA Prohibited List by name, though the list’s general categories can capture unlisted substances. Products sold as pinealon in other countries are research chemicals, and their sale for human use is not lawful. See our legal status overview, with detail for the UK, the US and Europe.

Pinealon is supplied as a freeze-dried powder that should be kept cold, dry and out of light; short peptides are relatively stable in this form. Once reconstituted, solutions are refrigerated and used within a limited period. See how to store peptides and our guide to bacteriostatic water.

A tripeptide is cheap and simple to synthesise, so the price of pinealon should reflect that, and the main question is whether a vial contains what it claims. Compare pinealon prices across suppliers, including listings in the UK and the US. A certificate of analysis should show a measured mass close to 418.4 g/mol and a purity figure from HPLC; see our list of third-party tested suppliers and suppliers that publish COAs, and our guide to spotting a fake supplier. If you are new to the category, what are research peptides explains the terms.